Skip to content

Explore the latest news and publications from Latigo Biotherapeutics

Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action

Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders.
Read more

Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines

Potential best-in-class lead program targets Nav1.8, a validated human target for pain.
Read more
Back To Top